Clinical Trials Logo

Filter by:
NCT ID: NCT05581303 Active, not recruiting - Clinical trials for Atherosclerotic Cardiovascular Disease

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Start date: December 14, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

NCT ID: NCT05580341 Active, not recruiting - Cervical Cancer Clinical Trials

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Start date: September 1, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the immunogenicity and safety of Zerun 9-valent HPV recombinant vaccine in healthy female 16-26 years of age by comparing with GARDASIL®9.

NCT ID: NCT05578521 Active, not recruiting - Clinical trials for Cerebral Small Vessel Diseases

CerebrAlcare Pills on CereBral Small VesseL DiseasE(CABLE)

Start date: June 5, 2022
Phase: Phase 4
Study type: Interventional

This is a randomized, double-blinded, placebo-controlled, multicenter trial. Cerebral small vessel disease (CSVD) patients will be diagnosed by Magnetic Resonance Imaging (MRI) and randomized into treatment or control groups. The purpose of this trial is to assess the efficacy of cerebralcare pills on cerebral small vessel disease.

NCT ID: NCT05578469 Active, not recruiting - Marfan Syndrome Clinical Trials

Surgical Treatment of Marfan Syndrome With Subluxation Lens

Start date: January 1, 2016
Phase:
Study type: Observational

To analyze the postoperative visual effects, and to compare the safety and efficacy of different surgical treatment with of Marfan Syndrome with subluxation lens.

NCT ID: NCT05576272 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Start date: May 19, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized, open, multicenter phase II/III trial to compare the efficacy and safety of QL1706 and carrilizumab combined with gemcitabine and cisplatin in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

NCT ID: NCT05575778 Active, not recruiting - Clinical trials for Critical Limb Ischemia

Peri-operative Foot CT Perfusion in CLI Patients

POP-CLI
Start date: October 1, 2022
Phase:
Study type: Observational

To investigate the clinical value of quantitative analysis of peri-operative foot supply through CT perfusion in patients with critical limb ischemia

NCT ID: NCT05575752 Active, not recruiting - Cognitive Function Clinical Trials

Acute Health Effects of High Temperature Exposure

Start date: October 23, 2022
Phase: N/A
Study type: Interventional

This is a randomized controlled human exposure crossover study. Investigators aims to assess the acute effects of high temperature exposure and the underlying mechanisms.

NCT ID: NCT05574920 Active, not recruiting - Breast Cancer Clinical Trials

Characterizing Breast Cancer With Al18F-NOTA-FAPI-04 PET/CT (PFB-02)

Start date: May 10, 2022
Phase: N/A
Study type: Interventional

Fibroblast activation protein (FAP) is overexpressed in cancer-associated fibroblasts (CAFs), which constitute a major proportion of cells within the tumor microenvironment, especially in breast cancer. Previous studies have demonstrated that FAPI PET/CT performs well in cases of epithelial tumors, including breast cancer. This prospective study is going to investigate the performance and value of Al18F-NOTA-FAPI-04 PET/CT in patients with breast cancer.

NCT ID: NCT05574907 Active, not recruiting - Breast Cancer Clinical Trials

Characterizing Breast Cancer With 68Ga-FAPI PET/CT (PFB-01)

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

Fibroblast activation protein (FAP) is overexpressed in cancer-associated fibroblasts (CAFs), which constitute a major proportion of cells within the tumor microenvironment, especially in breast cancer. 68Ga-FAPI has been developed as a tumor-targeting agent. This prospective study is going to investigate the performance and value of 68Ga-FAPI PET/CT in patients with breast cancer.

NCT ID: NCT05574881 Active, not recruiting - Breast Cancer Clinical Trials

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Start date: September 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

To investigate the efficacy and safety of Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR+/HER2+ Metastatic Breast Cancer